$1.96
-0.04(-1.76%)
Mkt Cap $94M
$1.19
$4.64
52-Week Range
At a Glance
AI-generatedCassava Sciences, Inc.
8-K
Cassava Sciences, Inc. issued a press release on March 12, 2026, regarding results of operations and financial condition, attached as Exhibit 99.1. The filing is submitted under Item 2.02 and Item 9.01.$94M
Market Cap
—
Revenue
-$87M
Net Income
Employees30
Fundamentals
How The Business Makes Money
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001069530
ISINUS14817C1071
CUSIP14817C107
Phone512 501 2444
Address7801 North Capital of Texas Highway, Austin, TX, 78731, US
SEC EDGAR